LigaChem Bio Secures Sole Development Rights for B7-H4 ADC LNCB74, Buying Out NexImmune Partner

The Quick Take

• LigaChem Biosciences acquired sole development, manufacturing, and commercialization rights for its B7-H4 ADC LNCB74 from partner NexImmune.
• The transition converts LNCB74 from a co-development program into a fully LigaChem-controlled asset, strengthening the Korean biotech's ADC pipeline.
• The move positions LigaChem as the decision-making authority on clinical development pace, licensing terms, and geographic commercialization strategy.

LigaChem Biosciences' acquisition of sole development rights for LNCB74 — its B7-H4 antibody-drug conjugate program — from co-development partner NexImmune marks a strategic consolidation of its pipeline around proprietary ADC assets. ADC technology has become one of oncology's most competitive fields, with major pharmaceutical companies paying multi-billion dollar premiums for validated ADC platforms and promising pipeline candidates. By converting LNCB74 from a shared program into a wholly owned asset, LigaChem eliminates partnership decision-making friction and retains full economics from any future licensing or out-licensing transactions.

For Korea's broader biotech investment landscape, LigaChem's strategic move signals growing confidence among domestic developers to own full rights to their ADC assets rather than co-develop with foreign partners at an early stage. The B7-H4 target is a validated oncology antigen with active programs from major players, making LNCB74 a potentially licensable asset to large pharma once clinical data matures. LigaChem's established ADC platform — already validated through its ConjuAll technology and multiple co-development deals — gives the company the manufacturing credibility to take LNCB74 forward independently rather than requiring a technology partner for execution.

Key signals to watch include LigaChem's announcement of LNCB74's next clinical development milestone — whether IND filing, Phase 1 dose-escalation, or partnering deal — following the rights consolidation. The macro variable is the global ADC licensing deal environment, which has seen landmark transactions including AbbVie's $10B ImmunoGen acquisition and several multi-billion deals in 2024-2025. If large-pharma ADC acquisition appetite continues, a program with validated B7-H4 targeting and a proven Korean ADC platform behind it becomes a high-priority licensing target. Korean biotech index performance and FII flows into Korea healthcare stocks will reflect this thesis.

Synthesized from 2 sources.